CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.

Front Oncol · 2020 · PMC7347039 · PMID 32714866

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

did not reach statistical significancep = 0.082so close (0.05 < p ≤ 0.1)

Influence of CXCL9 Expression on OS and TCGA Validation Lung adenocarcinoma patients with high CXCL9 levels had an 80% reduced risk of death ( HR = 0.20, 95% CI: 0.05–0.78, p = 0.021) relative to patients with low CXCL9 levels ( Table 4 ), although K–M analysis did not reach statistical significance (log-rank test p = 0.082; Supplement Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.